← FDA DRUG APPROVALS

FDA ANDA · ANDA217543

ORIGINAL STRENGTH HEARTBURN PREVENTION

famotidine

Sponsor: MARKSANS PHARMA

APPLICATION
ANDA217543
TYPE
ANDA
ORIGINAL APPROVAL
2023-03-08
LATEST ACTION
2023-03-08
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Over-the-counter

Products

FAMOTIDINEOver-the-counter
FAMOTIDINE 10MG · TABLET · ORAL
FAMOTIDINEOver-the-counter
FAMOTIDINE 20MG · TABLET · ORAL

Approval history

2023-03-08UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →